Paul A. Reyfman
0000-0002-6435-6001
Publication & Citation Trends
Most Cited Works
Publications
80 total
Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial.
Cited by 4
Semantic Scholar
Mitochondrial integrated stress response controls lung epithelial cell fate PDF
Cited by 144
OpenAlex
Association of changes in self-reported cough severity and cough-induced stress urinary incontinence (phase 3b gefapixant trial)
Cited by 0
Semantic Scholar
Gefapixant efficacy and safety in participants with history of refractory or unexplained chronic cough for ≥1 vs <1 year
Cited by 0
Semantic Scholar
S3 Gefapixant efficacy and safety in participants with history of refractory or unexplained chronic cough for ≥1 vs <1 year OA
Cited by 0
Semantic Scholar
S1 A phase 3b trial of gefapixant, a P2X3-receptor antagonist, in women with chronic cough and stress urinary incontinence OA
Cited by 1
Semantic Scholar
Patient-reported cough severity in women with chronic cough and stress urinary incontinence treated with gefapixant
Cited by 1
Semantic Scholar
Burden of disease in a phase 3b trial of gefapixant in women with chronic cough and stress urinary incontinence
Cited by 1
Semantic Scholar
Research Topics
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
(19)
Chronic Obstructive Pulmonary Disease (COPD) Research
(10)
Neonatal Respiratory Health Research
(9)
Immune cells in cancer
(7)
COVID-19 Clinical Research Studies
(6)
Frequent Co-Authors
Affiliations
Northwestern University
Merck & Co., Inc., Rahway, NJ, USA (United States)
Harvard University
Medizinische Hochschule Hannover
University of Chicago Medical Center